Amsterdam UMC

• Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients with Cardiogenic Shock f… Recruiting
  2024-510892-40-00 Phase IV 9 countries
• FAPi-PET imaging of in vivo early fistula healing in perianal Crohn’s disease: PERSIST study Recruiting
  2023-505317-25-00 Phase IV 1 country
• Prevention of opioid-induced constipation in patients with advanced cancer. Recruiting
  2023-509462-38-00 Phase III/IV 1 country MAGNESIUM HYDROXIDE; SODIUM HYDROGEN CARBONATE, POTASSIUM CHLORIDE, SODIUM CHLOR…
• A phase 1b-2 study of mitomycin-C / capecitabine chemoradiotherapy combined with ipilumimab and nivolumab or nivolumab monotherapy as bladde… Ended
  2023-509460-19-00 Phase I/II 1 country CAPECITABINE; IPILIMUMAB; MITOMYCIN; NIVOLUMAB
• Rivaroxaban Monotherapy and CYP2C19 Genotype Testing in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention Ended
  2023-508904-39-00 Phase IV 1 country RIVAROXABAN
• TGF‐β And PDL‐1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY) Ended
  2023-503312-32-00 Phase II 1 country BINTRAFUSP ALFA
• Evaluating T Cell Changes and Activation in Cancer Patient Using Two PET Tracers (iRelate) Ended
  2023-509486-20-00 Phase II/III 1 country ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM
• Aspirin to prevent cardiovascular events in patients with pneumonia or influenza Ended
  2023-504553-12-01 Phase IV 1 country ACETYLSALICYLIC ACID; PANTOPRAZOLE
• DUPI REDUCE trial (DUPIlumab dose REDUCtion in patients with controlled atopic Eczema): a multicenter, low-intervention, non-inferiority ran… Ended
  2023-504171-24-00 Phase IV 1 country DUPILUMAB
• Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS Ended
  2022-502664-21-00 Phase IV 1 country OCRELIZUMAB; RITUXIMAB
• LEGACY Ended
  2023-504360-42-00 Phase IV 2 countries ACETYLSALICYLIC ACID
• Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle… Ended
  2023-509380-24-00 Phase II 1 country RETIFANLIMAB
• Blood-borne Assessment of Stromal activation in esophageAL adenocarcinoma to guide tocilizumab Therapy: a randomized phase II proof-of-conce… Ended
  2023-509458-77-00 Phase II 1 country
• A Randomized Controlled Phase II Clinical Trial with Intradermal IMO-2125 (Tilsotolimod) in pT3-4 cN0M0 Melanoma (Intrim 1 study) Ended
  2023-509461-20-00 Phase II 1 country TILSOTOLIMOD SODIUM
• A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in pati… Ended
  2023-509463-24-01 Phase II 4 countries FLUOROURACIL; IRINOTECAN; TEGAFUR, GIMERACIL, OTERACIL
• Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX) Ended
  2023-509287-26-00 Phase II 1 country CAPECITABINE; CARBOPLATIN; FLUOROURACIL; IRINOTECAN; NIVOLUMAB; OXALIPLATIN
• ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) study: safety, toxicity and immunological effects of peritumorally delivered immunotherap… Ended
  2023-505968-11-00 Phase I (Other) 1 country
• Unravelling intestinal fibrosis in ulcerative colitis: INTERACT study Ended
  2023-507907-73-00 Phase III/IV 1 country GALLIUM (68GA) CHLORIDE
• Treating discharge and discomfort of eye prosthesis: a comparison between vitamin A ointment, anti-inflammatory eye drops and standard eye d… Ended
  2023-504451-27-01 Phase IV 1 country FLUOROMETHOLONE; SODIUM HYALURONATE, CARBOMER 981
• Stopstudy Ended
  2023-505143-39-00 Phase IV 1 country ESTRADIOL; ESTRADIOL VALERATE
• DiEtary Sodium Intake effects on ertugliflozin-induced changes in GFR, reNal oxygenation and systemic hemodynamics: the DESIGN study, a rand… Ended
  2023-510257-42-01 Phase IV 1 country ERTUGLIFLOZIN
• Guanabenz in VWM Ended
  2023-503320-89-00 Phase I/II 1 country GUANABENZ ACETATE
• Study of Pembrolizumab combined with Ataluren in Patients with metastatic pMMR and dMMR colorectal cancer adenocarcinomas or metastatic dMMR… Ended
  2023-509457-31-00 Phase I/II 1 country

Showing 25–47 of 47 trials